Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety-related counseling statements align with label sections on skeletal muscle and liver dysfunction, but multiple statements about diabetes/glucose effects and pregnancy use are not supported by the provided label text, and some monitoring/counseling specifics exceed what is explicitly stated.
Category Scores
Accurate Statements
Atorvastatin can cause muscle injury ranging from mild muscle aches to rarer, more serious problems like myopathy or rhabdomyolysis.
Label Warnings and Precautions 5.1 (myopathy; rare rhabdomyolysis) and 17.1 (risk of myopathy and reporting muscle pain).
Risk of muscle injury is higher with higher doses of statins.
Label 5.1 discusses increased risk with higher doses in the context of interacting drugs (e.g., exceeding doses); Tables and 5.1 note risk increases with higher doses during interacting therapy.
Risk of muscle injury is higher with kidney disease.
Label 5.1 states: 'A history of renal impairment may be a risk factor for the development of rhabdomyolysis.'
Patients should report unexplained muscle pain, weakness, or dark urine promptly.
Label 5.1 (report unexplained muscle pain/tenderness/weakness particularly with malaise or fever) and 5.1 (rhabdomyolysis with myoglobinuria—dark urine implied in counseling context).
Statins can raise liver enzymes.
Label 5.2 (biochemical abnormalities of liver function; 'Persistent elevations' and increases in transaminases).
Clinicians typically check liver tests before starting a statin.
Label 5.2: 'recommended that liver function tests be performed prior to...' and 17.2.
Clinicians may re-check liver tests if symptoms occur.
Label 5.2: 'Patients who develop increased transaminase levels should be monitored until the abnormalities resolve' and dose-elevation monitoring schedule; however symptom-based re-checking is not explicitly enumerated beyond monitoring until resolution.
Symptoms that may prompt liver test re-check include unusual fatigue, loss of appetite, upper belly pain, dark urine, or yellowing of the skin or eyes.
Not explicitly listed in provided label text; only jaundice is mentioned in clinical trials. This statement is therefore partially unsupported (see unsupported section).
Some medications can increase the amount of atorvastatin in the body.
Label 7 (increases in plasma concentrations with strong CYP3A4 inhibitors) and 5.1 (concomitant use increases risk).
Risk of muscle injury is higher in people with certain drug interactions.
Label 5.1 and 7: increased risk of myopathy/rhabdomyolysis with cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, protease inhibitors, niacin, azole antifungals.
All current medications and supplements should be discussed before starting (or continuing) Lipitor to check for interactions.
Label 17.1: 'They should discuss all medication, both prescription and over the counter, with their healthcare professional.' and 17 counseling mentions informing other healthcare professionals.
Kidney and liver problems should be discussed before starting (or continuing) Lipitor.
Label 5.1 (renal impairment as risk factor) and 5.2 (caution with substantial alcohol/liver disease; active liver disease/unexplained persistent transaminase elevations are contraindications—though the contraindication section text is not provided beyond a reference).
Pregnancy plans should be discussed before starting or continuing Lipitor because statins are generally not used during pregnancy.
Label 4.3 indicates women who are pregnant/may become pregnant are contraindicated (may cause fetal harm) and LIPITOR should be discontinued if pregnancy occurs.
Unsupported Statements
Lipitor (atorvastatin) is commonly used in people with diabetes to lower cholesterol and reduce cardiovascular risk.
Provided label text supports use in 'patients with type 2 diabetes' for reducing MI and stroke risk, but does not support statements about being 'commonly used' or specifically 'to lower cholesterol' in diabetes.
Statins, including atorvastatin, can slightly increase blood glucose in some people.
No glucose/blood sugar elevation claim appears in the provided label text sections.
In some studies, statins have been associated with a higher risk of developing diabetes in people who were at risk.
No such claims appear in the provided label text.
In someone who already has diabetes, the blood glucose effects of statins usually do not mean stopping the drug.
No blood glucose effect or guidance about not stopping is stated in the provided label text.
Glucose control monitoring is recommended, especially after starting or changing the dose.
No glucose monitoring recommendation is present in the provided label text; only liver function test monitoring is explicitly described.
Atorvastatin can cause muscle injury ranging from mild muscle aches to rarer, more serious problems like myopathy or rhabdomyolysis.
Partially supported (myopathy defined and rhabdomyolysis described as rare), but severity spectrum phrasing is not directly stated as such; grading kept as accurate in warnings section. If treated strictly as a claim, label supports myopathy and rare rhabdomyolysis, so not included here.
The likelihood of side effects can increase when diabetes is complicated.
No statement in provided label ties adverse effect likelihood to 'complicated diabetes' specifically.
The likelihood of side effects can increase with heavy alcohol use.
Label 5.2 supports caution with substantial alcohol consumption, but this is not framed as 'likelihood of side effects' broadly; still largely implied. Considered partially supported; not included as contradiction.
The likelihood of side effects can increase with significant kidney or liver disease.
Renal impairment is described as a risk factor for rhabdomyolysis and liver disease is mentioned as a caution/contraindication topic, but the label text does not explicitly state 'likelihood of side effects' generally; partially supported but not explicitly stated as written.
After starting Lipitor, calling a clinician quickly is recommended for any meaningful worsening in blood sugar control that does not make sense based on diet or medication changes.
No blood sugar worsening monitoring or counseling language appears in provided label text.
Diabetics often need more frequent glucose monitoring when starting a statin or increasing the dose.
No glucose monitoring frequency recommendation appears in provided label text.
In people with diabetes and high cholesterol, statins like Lipitor are prescribed to lower LDL cholesterol.
Label provided does not state this diabetes/high cholesterol-to-LDL counseling linkage; it includes lipid-altering indications and separate diabetes risk reduction indications.
In people with diabetes and high cholesterol, statins like Lipitor are prescribed to reduce the risk of heart attack and stroke.
Supported for reducing MI and stroke risk in type 2 diabetes with multiple risk factors (label 1.1), but 'heart attack and stroke' correspond to MI and stroke respectively; this is supported with slight terminology mapping. Not included as unsupported.
Statins provide cardiovascular benefit that is the usual rationale for use in diabetes, even with the small glucose-related risk.
While label supports CV risk reduction in type 2 diabetes, the 'small glucose-related risk' premise is not supported by provided label text.
Clinicians may re-check liver tests if symptoms occur.
Label supports monitoring until abnormalities resolve and prescribes specific testing time points (prior, 12 weeks after initiation and after dose elevation, then periodically). It does not explicitly instruct symptom-triggered re-checking; thus the 'if symptoms occur' portion is unsupported.
Symptoms that may prompt liver test re-check include unusual fatigue, loss of appetite, upper belly pain, dark urine, or yellowing of the skin or eyes.
Provided label text explicitly mentions jaundice as observed in one patient and discusses monitoring abnormal transaminases; it does not list a symptom cluster (fatigue, loss of appetite, right upper abdominal pain, etc.) as triggers for liver test re-check.
After starting Lipitor, calling a clinician quickly is recommended for new or worsening muscle pain or weakness, especially if accompanied by fever or feeling very unwell.
Label 5.1 advises reporting muscle pain/tenderness/weakness particularly if accompanied by malaise or fever. This is supported. Not included.
After starting Lipitor, calling a clinician quickly is recommended for dark-colored urine.
Label 5.1 mentions rhabdomyolysis with acute renal failure secondary to myoglobinuria; however explicit patient counseling 'dark-colored urine' is not directly spelled out in the provided label text. Partially supported; treated as unsupported due to lack of explicit counseling phrase.
After starting Lipitor, calling a clinician quickly is recommended for signs of liver problems including yellow eyes or skin, severe nausea, right upper abdominal pain, or unusual tiredness.
Provided label text does not list severe nausea, right upper abdominal pain, or unusual tiredness as signs warranting prompt action; only jaundice and general liver enzyme monitoring are discussed.
Risk of muscle injury is higher in people with certain drug interactions.
Supported generally by label 5.1 and 7; however the user's list includes 'certain drug interactions' without specifics—still supported. Not included.
Risk of muscle injury is higher with higher doses of statins.
Supported in the label primarily in the context of interacting drugs (e.g., exceeding certain atorvastatin dose thresholds with strong inhibitors). As a general statement, it is not fully explicit in the provided text.
History of statin intolerance matters when deciding dose and monitoring.
No explicit mention of 'statin intolerance history' appears in provided label text.
History of unexplained muscle problems matters when deciding dose and monitoring.
Label advises discontinuation if myopathy is diagnosed or suspected, but does not explicitly mention history of prior unexplained muscle problems as decision criteria.
History of significant liver issues matters when deciding dose and monitoring.
Label discusses caution in liver disease and contraindications, but does not explicitly frame 'history of significant liver issues' as a dose/monitoring decision factor in the provided text.
Reviewing a full medication list with a pharmacist or prescriber is advised for diabetics taking multiple medications due to interaction risk.
Label advises discussing all medications with healthcare professional, but does not mention pharmacists specifically nor tie to diabetics.
Some medications that increase atorvastatin levels can raise the chance of side effects, especially muscle toxicity.
Label supports increased risk of myopathy/rhabdomyolysis with strong CYP3A4 inhibitors and cyclosporine, but the 'especially muscle toxicity' phrasing is not directly stated as such; however it is largely consistent with the myopathy/rhabdomyolysis risk. Not included as unsupported.
Contradictions
Low
AI Statement
In someone who already has diabetes, the blood glucose effects of statins usually do not mean stopping the drug.
Label Reference
No supporting label text provided; not a direct contradiction to the label, so severity kept as none. If forced to treat as contradiction, label would need explicit contrary guidance. Not applied here.
Important Omissions
For type 2 diabetes indication: label specifies patients without clinically evident coronary heart disease but with multiple risk factors (e.g., retinopathy, albuminuria, smoking, hypertension) for MI/stroke risk reduction; AI did not capture these qualifiers.
Importance:
Moderate
Monitoring language in label explicitly specifies liver function tests prior to and at 12 weeks after initiation and after dose increase, and periodically thereafter; AI did not include these timepoints.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most muscle and liver counseling aligns with label. However, glucose-related claims and glucose monitoring recommendations are unsupported by the provided label text and could lead to inappropriate emphasis on glycemic changes. Liver symptom cluster and dark urine counseling for liver problems are also not explicitly supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Diabetes/glucose-effect and glucose-monitoring statements are not supported by the provided label text; several detailed liver- and dark-urine/urgent-calling symptom lists are not explicitly present in the provided label.
Suggested Improvement
Remove or rewrite glucose-related claims unless supported by the supplied label sections; align monitoring instructions to label-specified liver function test timepoints (prior to, at 12 weeks after initiation and dose increases, then periodically) and limit urgent-calling symptom guidance to what is explicitly stated (unexplained muscle pain/tenderness/weakness with malaise/fever; liver enzyme monitoring and jaundice mention). For the diabetes indication, include the label’s qualifiers (type 2 diabetes without clinically evident CHD and with multiple risk factors such as retinopathy/albuminuria/smoking/hypertension).